Distinct from classic “one drug, one target” therapeutics, ST266 contains numerous biologic components at physiologic concentrations which function in combination and synergistically to yield anti-inflammatory, neuroprotective, anti-apoptotic and vascular integrity preservative activities. Noveome has 50 issued U.S. patents and several others pending covering its ST266 product and its use. In addition, Noveome has over 40 granted patents in major global markets including Europe, Japan, China and Canada.
In a single "lock and key" approach, an antibody hits a single receptor on a cell.
ST266 provides multiple signals at physiologic levels to unlock complex biologic processes.
Numerous preclinical and clinical studies have confirmed the safety of our novel approach. Findings from these studies also demonstrate the unique combination of biologic activities attributed to our secretome product, ST266. These attributes determine our indication selection and development programs.
ST266 can modulate the inflammatory response by decreasing vascular permeability, immune cell infiltration, and edema.
ST266 helps these wounds heal faster by facilitating the deposition, alignment and cross-linking of collagen fibers and matrix.
ST266 is neuroprotective and supports nerve regrowth. It decreases the rate of demyelination, and creates an environment that supports nerve repair.
ST266 improves function in damaged cells. It increases proliferation, reduces apoptosis, and helps restore homeostasis.
Phase I and II clinical trials have demonstrated the robust safety of ST266 when administered as ophthalmic, dermal, and oral formulations.
Noveome has a 30,000 square foot cGMP manufacturing facility in Pittsburgh, PA.
Our therapeutic approach has potential to be applied across a wide range of disease indications to improve patient outcomes. Learn More about our Pipeline »